TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD's stock experienced several events in the past six months. The company reported profitability in Q2 and Q3 2025. The stock price increased by 3.82% from January 2, 2025, to December 31, 2025. As of January 13, 2026, the stock price rose by 0.96% on the last trading day, but declined in 3 of the last 10 days. TXMD has shown an upward trend of 77.05% over the past six months. A sell signal was issued on January 9, 2026, leading to a -3.70% fall. Increased trading volume on falling prices on January 12, 2026, was noted. The company continues to explore strategic alternatives.

While direct demand seasonality for TherapeuticsMD's licensed products is not explicitly detailed, historically, buying TXMD stock in January has shown the highest probability of a positive return, while October has the lowest, suggesting a seasonal pattern in investor sentiment.

TherapeuticsMD, Inc. is a pharmaceutical company focused on women's health that transitioned to a royalty company in December 2022. The company licenses women's health products to partners, earning income from royalties. Key products include IMVEXXY for dyspareunia, BIJUVA for vasomotor symptoms, ANNOVERA as a contraceptive vaginal system, and vitaMedMD and BocaGreenMD prenatal vitamins.

TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida, with global operations and employees across North America, Europe, and Asia. The company licenses its women's health products in the United States and internationally through exclusive licensing partners.

TherapeuticsMD's brand reputation is tied to its financial performance as a royalty collector and the success of its licensing partners. The swing to profitability in Q2 2025 and ongoing evaluation of strategic alternatives could positively impact its reputation. No specific negative events significantly impacting TherapeuticsMD's brand reputation were identified within the past year.

TherapeuticsMD's ownership includes institutional investors (28.89%), individual insiders (1.62%), hedge funds (15.8%), and the general public (69.8%). Major institutional shareholders include Rubric Capital Management LP and The Vanguard Group, Inc. Insider buying activity has been observed, with Thomas Thompson, Chairman of the Board, buying 8,400 shares on December 22, 2025.